AstraZeneca buys ModellaAI. The priority is to accelerate the search for new medicines using artificial intelligence.
It is an unprecedented movement in the pharmaceutical and technological market: the AstraZeneca is buying Modella AI.
For the first time, according to AstraZeneca itself, this is the first time a major pharmaceutical company buys an artificial intelligence company (IA).
The priority is clear: accelerate the search for new medicines using AI.
The acquisition will significantly accelerate efforts to quantitative pathology and biomarker discoverycommented Aradhana Sarin, financial director of AstraZeneca.
The goal is to improve computerized analysis of tissue samples to develop accurate biomarkers and, based on these biomarkers, create personalized therapies.
Modella’s technology will be integrated into research and development in oncology.
“O Cancer drug development is becoming increasingly complexdata-based, and time-sensitive”, explained Gabi Raia, sales director at Modella AI, this Tuesday, during the JP Morgan conference.
The merger between AstraZeneca and Modella AI will allow the use of proprietary tools in global studies and clinical environments, analyzes .
Sarin added that AI tools can be used to choose patients for drug trials more quickly; this can increase the chances of clinical success and reduce costs.
No financial details about this operation were revealed.
